Immunic (in discussions with Roche) plans to conduct FDA regulatory meetings for two...
Euan MacDonald Centre launches motor neurone disease trials in UK
The Euan MacDonald Centre at the University of Edinburgh has launched a clinical drug trial for Motor Neurone Disease (MND).
Veristat buys The Clinical Trial Company to boost presence in Europe
Full-service contract research organisation (CRO) Veristat has bolstered its footprint in Europe with the acquisition of The Clinical Trial Company (TCTC Group), also a CRO.
Acceleron’s ACE-083 could succeed in muscle growth but long-term functional benefit may be limited
Phase II Charcot-Marie-Tooth (CMT) disease trial fails to address the underlying nerve degeneration.
BrainStorm Cell Therapeutics to continue multiple sclerosis trial
BrainStorm Cell Therapeutics has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase II clinical trial of NurOwn in progressive multiple sclerosis patients.
Lilly initiates real-world study of migraine drug Emgality
Eli Lilly has initiated a real-world evidence study, named TRIUMPH, to compare Emgality (galcanezumab-gnlm) to other migraine preventive treatments.
Biohaven reports positive data from migraine trial of vazegepant
Biohaven Pharmaceutical has reported positive findings from the Phase II/III clinical trial that assessed vazegepant for the acute treatment of migraine.
Amylyx’s ALS drug slows disease progression in Phase II trial
Amylyx Pharmaceuticals has reported that its investigational therapy, AMX0035, slowed disease progression in the Phase II CENTAUR study for amyotrophic lateral sclerosis (ALS) treatment.
Axsome’s Phase III GEMINI trial of depression drug meets endpoints
Axsome Therapeutics has reported positive results from the Phase III GEMINI clinical trial of AXS-05 in patients with major depressive disorder (MDD).
Biogen to drop gosuranemab development after Phase II failure
Biogen has announced plans to discontinue the development of gosuranemab (BIIB092) after the drug failed to yield positive results in the Phase II PASSPORT clinical trial to treat progressive supranuclear palsy (PSP).